Adam Maeder Analyst Performance

Research Analyst at Piper Sandler

Adam Maeder is a stock analyst at Piper Sandler in the medical sector, covering 13 publicly traded companies. Over the past year, Adam Maeder has issued 16 stock ratings, including buy and hold recommendations. While full access to Adam Maeder's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Adam Maeder's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

50 Last 5 Years

Buy Recommendations

74.42% 32 Buy Ratings

Companies Covered

13 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	74.4%	32 ratings
Hold	25.6%	11 ratings
Sell	0.0%	0 ratings

Out of 43 total stock ratings issued by Adam Maeder at Piper Sandler, the majority (74.4%) have been Buy recommendations, followed by 25.6% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  TMDI

  Dec 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  TCMD

  Nov 2021

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NYSE	53.8% of companies on NYSE	7 companies
NASDAQ	46.2% of companies on NASDAQ	6 companies

Adam Maeder, an analyst at Piper Sandler, currently covers 13 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 13 companies	100.0%

Adam Maeder of Piper Sandler specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED INSTRUMENTS 5 companies	38.5%
SURGICAL & MEDICAL INSTRUMENTS 5 companies	38.5%
MED PRODUCTS 2 companies	15.4%
MEDICAL INFO SYS 1 company	7.7%

About Adam Maeder

Adam Maeder is a managing director and senior research analyst focused on the medical technology sector. Prior to joining Piper Sandler in 2019, Maeder worked in medical technology equity research at Wells Fargo Securities. Additionally, he worked at Westwicke Partners providing investor relations strategy and capital markets advisory to medical technology and diagnostics companies. Maeder began his career working on the equity capital markets desk at Piper Sandler. Maeder holds a BBA in finance from the University of Iowa.

Follow on LinkedIn

Adam Maeder's Ratings History at Piper Sandler

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
RBOT Vicarious Surgical	8/13/2025	Lower Price Target	$9.25	$7.00	Neutral	$0.00 00.00% ROI
INSP Inspire Medical Systems	8/5/2025	Lower Price Target	$130.79	$150.00	Overweight	$0.00 00.00% ROI
RMD ResMed	8/1/2025	Boost Price Target	$272.16	$270.00	Neutral	$0.00 00.00% ROI
EW Edwards Lifesciences	7/25/2025	Boost Price Target	$79.41	$90.00	Overweight	$0.00 00.00% ROI
ISRG Intuitive Surgical	7/23/2025	Reiterated Rating	$496.23	$595.00	Overweight	$0.00 00.00% ROI
NSPR InspireMD	5/12/2025	Lower Price Target	$2.54	$4.00	Overweight	$0.00 00.00% ROI
TCMD Tactile Systems Technology	5/6/2025	Downgrade	$13.94	$14.00	Neutral	$0.00 00.00% ROI
EW Edwards Lifesciences	4/24/2025	Upgrade	$70.33	$80.00	Overweight	$0.00 00.00% ROI
ISRG Intuitive Surgical	4/23/2025	Lower Price Target	$492.31	$575.00	Overweight	$0.00 00.00% ROI
ABT Abbott Laboratories	4/17/2025	Reiterated Rating	$131.84	$145.00	Overweight	$0.00 00.00% ROI
RXST RxSight	4/15/2025	Initiated Coverage	$14.42	$18.00	Neutral	$0.00 00.00% ROI
RBOT Vicarious Surgical	3/18/2025	Lower Price Target	$9.10	$8.50	Neutral	$0.00 00.00% ROI
EW Edwards Lifesciences	2/12/2025	Boost Price Target	$75.47	$73.00	Neutral	$0.00 00.00% ROI
INSP Inspire Medical Systems	2/10/2025	Lower Price Target	$182.00	$233.00	Overweight	$0.00 00.00% ROI
NVRO Nevro	2/7/2025	Upgrade	$5.73	$5.85	Overweight	$0.00 00.00% ROI
ISRG Intuitive Surgical	1/24/2025	Reiterated Rating	$587.08	$670.00	Overweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.